{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:03:40Z","timestamp":1792746220238,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019778","name":"President's Malaria Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>From August to October 2022, a therapeutic efficacy study of Niger\u2019s first-line antimalarial, artemether-lumefantrine (AL), was conducted in four sites (Aderbissinat, Boboye, Agui\u00e9, and Baban Tabki) to evaluate its therapeutic efficacy and investigate for molecular markers of antimalarial drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Children aged 5 to 15\u00a0years old with uncomplicated malaria were assessed in a 28\u00a0day in vivo efficacy study. Genotyping using three markers (\n                      <jats:italic>msp1, msp2<\/jats:italic>\n                      and the PolyA microsatellite) and match counting using the WHO three-out-of-three algorithm, were used to distinguish recrudescences from new infections. A two-out-of-three algorithm was also utilized as a sensitivity analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PCR uncorrected and corrected efficacy results at day 28 were calculated. Resistance markers were analysed by next-generation sequencing. Uncorrected treatment efficacies were 62.0% (95% CI 54\u201374) in Aderbissinat, 95.4% (95% CI 91\u2013100) in Agui\u00e9, 98.7% (95% CI 96\u2013100) in Boboye, and 50.6% (95% CI 42\u201362) in Baban Tabki. After PCR correction, AL efficacy was 100%, 97.5%, 100%, and 93.5%, respectively. Marker analysis revealed a high prevalence\n                      <jats:italic>of S108N, C59R,<\/jats:italic>\n                      and\n                      <jats:italic>N51I<\/jats:italic>\n                      mutations in the\n                      <jats:italic>pfdhfr<\/jats:italic>\n                      gene, and\n                      <jats:italic>S436A<\/jats:italic>\n                      and\n                      <jats:italic>A437G<\/jats:italic>\n                      mutations in the\n                      <jats:italic>pfdhps<\/jats:italic>\n                      gene. No validated or candidate\n                      <jats:italic>pfkelch13<\/jats:italic>\n                      mutations were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In all four sites evaluated, AL retains therapeutic efficacies above the 90% WHO-recommended threshold using the primary three-out-of-three match criteria. In Agui\u00e9 and Baban Tabki, efficacy remained above the threshold with certain match criteria and statistical approaches but fell below the cutoff using two-out-of-three matching and per-protocol methods, suggesting emerging efficacy concerns in southern parts of the country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-025-05679-x","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:51Z","timestamp":1767028611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022"],"prefix":"10.1186","volume":"24","author":[{"given":"Ibrahim Maman","family":"Laminou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoussi Maman","family":"Kabirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima Issa","family":"Arzika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdou","family":"Yahaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa Bineta","family":"Deme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Alpha","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassirou","family":"Ngom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efta","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djiby","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilahatou","family":"Bahari-Tohon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Sanoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cavros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"5679_CR1","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","author":"WHO","year":"2024","unstructured":"WHO. World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024."},{"key":"5679_CR2","unstructured":"WHO. World Malaria Report 2023. Geneva: World Health Organization. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"5679_CR3","unstructured":"Niger National Institute of Statistics. 2021 Niger Malaria Indicator Survey (MIS). Niamey, Niger, 2021."},{"key":"5679_CR4","unstructured":"Programme National de Lutte contre le Paludisme. Directives Nationales de Lutte Contre le Paludisme dans les Formations Sanitaires au Niger. Niamey, Niger."},{"key":"5679_CR5","first-page":"79","volume":"14","author":"A Salissou","year":"2012","unstructured":"Salissou A, Halima B, Abani M, Adehossi E, Daou M, Boureima S. Efficacy and tolerability of the combination artemether lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Niger. Univ Lome Sci J Res. 2012;14:79\u201384.","journal-title":"Univ Lome Sci J Res"},{"key":"5679_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12936-024-04945-8","volume":"23","author":"IM Laminou","year":"2024","unstructured":"Laminou IM, Issa I, Adehossi E, Maman K, Jackou H, Coulibaly E, et al. Therapeutic efficacy and tolerability of artemether\u2013lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020. Malar J. 2024;23:144.","journal-title":"Malar J"},{"key":"5679_CR7","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5679_CR8","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. Geneva: World Health Organization. 2007 https:\/\/www.who.int\/publications-detail-redirect\/9789241596305. Accessed 14 Apr 2024."},{"key":"5679_CR9","unstructured":"MaRS Protocol. U.S. centers for disease control and prevention; 2023. https:\/\/cdcgov.github.io\/MaRS\/."},{"issue":"11","key":"5679_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00153-8","volume":"5","author":"A Schnoz","year":"2024","unstructured":"Schnoz A, Beuret C, Concu M, Hosch S, Rutaihwa LK, Golumbeanu M, et al. Genotyping methods to distinguish Plasmodium falciparum recrudescence from new infection for the assessment of antimalarial drug efficacy: an observational, single-centre, comparison study. Lancet Microbe. 2024;5(11):100914. https:\/\/doi.org\/10.1016\/S2666-5247(24)00153-8.","journal-title":"Lancet Microbe"},{"key":"5679_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"5679_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12936-021-03760-9","volume":"20","author":"Y Diarra","year":"2021","unstructured":"Diarra Y, Kon\u00e9 O, Sangar\u00e9 L, Doumbia L, Haidara DBB, Diallo M, et al. Therapeutic efficacy of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015\u20132016. Malar J. 2021;20:235.","journal-title":"Malar J"},{"key":"5679_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155\u201361. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.001.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5679_CR14","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(20)30493-X","volume":"21","author":"NK Kayiba","year":"2021","unstructured":"Kayiba NK, Yobi DM, Tshibangu-Kabamba E, Tuan VP, Yamaoka Y, Devleesschauwer B, et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infect Dis. 2021;21:e82-92.","journal-title":"Lancet Infect Dis"},{"key":"5679_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5679_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"5679_CR17","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J Infect Dis. 2022;225(8):1411\u20134. https:\/\/doi.org\/10.1093\/infdis\/jiab352.","journal-title":"J Infect Dis"},{"key":"5679_CR18","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:6353.","journal-title":"Nat Commun"},{"key":"5679_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad MD, Asua V, Garg S, Giesbrecht D, Niar\u00e9 K, Smith S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389:722\u201332.","journal-title":"N Engl J Med"},{"key":"5679_CR20","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8:1911\u20139.","journal-title":"Nat Microbiol"},{"key":"5679_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P, et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389:1191\u2013202.","journal-title":"N Engl J Med"},{"key":"5679_CR22","doi-asserted-by":"crossref","unstructured":"Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medrxiv. 2023 (preprint).","DOI":"10.1101\/2023.11.07.23298207"},{"key":"5679_CR23","doi-asserted-by":"crossref","unstructured":"Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study. medRxiv. 2024 (preprint).","DOI":"10.2139\/ssrn.4726181"},{"issue":"1","key":"5679_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/infdis\/jiae425","volume":"231","author":"JE Laury","year":"2025","unstructured":"Laury JE, Mugittu K, Kajeguka DC, Kamugisha E, Ishengoma DS, Mandara CI, et al. Efficacy and safety of artemether-lumefantrine against uncomplicated falciparum malaria infection in Tanzania, 2022: a single-arm clinical trial. J Infect Dis. 2025;231(1):251\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiae425.","journal-title":"J Infect Dis"},{"issue":"5","key":"5679_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JAMMR\/2017\/34192","volume":"22","author":"I Laminou","year":"2017","unstructured":"Laminou I, Lamine M, Mahamadou B, Ascofar\u00e9 O, Dieye A. Polymorphism of pfk13-propeller in Niger: detection of novel mutations. J Adv Med Med Res. 2017;22(5):1\u20135. https:\/\/doi.org\/10.9734\/JAMMR\/2017\/34192.","journal-title":"J Adv Med Med Res"},{"key":"5679_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12936-023-04571-w","volume":"22","author":"II Arzika","year":"2023","unstructured":"Arzika II, Lobo NF, Lamine MM, Tidjani IA, Sandrine H, Sarrasin-Hubert V, et al. Plasmodium falciparum kelch13 polymorphisms identified after treatment failure with artemisinin-based combination therapy in Niger. Malar J. 2023;22:142.","journal-title":"Malar J"},{"issue":"8","key":"5679_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7080155","volume":"7","author":"I Issa","year":"2022","unstructured":"Issa I, Lamine MM, Hubert V, Ilagouma A, Adehossi E, Mahamadou A, et al. Prevalence of mutations in the Pfdhfr, Pfdhps, and Pfmdr1 genes of malarial parasites isolated from symptomatic patients in Dogondoutchi, Niger. Trop Med Infect Dis. 2022;7(8):155. https:\/\/doi.org\/10.3390\/tropicalmed7080155.","journal-title":"Trop Med Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05679-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:53Z","timestamp":1767028613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-025-05679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5679"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05679-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}